Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

46.94 +2.38 (+5.34%)
Streaming Delayed Price Updated: 11:40 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
From Harrow, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
From Pomerantz LLP
Via GlobeNewswire
News headline image
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
From Harrow, Inc.
Via Business Wire
News headline image
Harrow to Present at Two Investor Conferences in May
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Announces First-Quarter 2025 Financial Results
From Harrow, Inc.
Via Business Wire
News headline image
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
From Harrow, Inc.
Via Business Wire
News headline image
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Launches VEVYE® Access for All
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
From Harrow, Inc.
Via Business Wire
News headline image
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
From Harrow, Inc.
Via Business Wire
News headline image
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
From Harrow, Inc.
Via Business Wire
News headline image
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
From Harrow, Inc.
Via Business Wire
News headline image
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.